We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > NantKwest

News List

ImmunityBio and NantKwest announce merger expresspharma
December 22, 2020
Merged entity brings together 11 Phase II / III clinical trials across oncology and infectious disease that use combined immunotherapy platforms.
ImmunityBio, NantKwest begin patient dosing in Phase 1 clinical trial of COVID-19 vaccine candidate expresspharma
October 22, 2020
The Phase 1 trial, being conducted at the Hoag Hospital in Newport Beach, California, is enrolling healthy adult subjects up to age 55 to examine the safety and reactogenicity of two doses of the vaccine candidate.
NantKwest and ImmunityBio to initiate a phase 2 study of immunotherapy for metastatic pancreatic can pharmaceutical-business-review
May 20, 2020
NantKwest announced plans for a Phase 2, randomized, open-label study to evaluate the efficacy and safety of their combination immunotherapy.
NantKwest and ImmunityBio work on Covid-19 vaccines and drugs pharmaceutical-technology
April 16, 2020
NantKwest and its sister firm ImmunityBio have partnered for the development of potential vaccines and therapeutics against Covid-19.
NantKwest and ProMab partner to develop NK cell therapies pharmaceutical-technology
March 06, 2019
Immunotherapy company NantKwest has partnered with ProMab Biotechnologies with the aim of developing a select next generation targeted natural killer (NK) cell therapy.